Clinical Study Supports Prothea’s Vision of Image-Guided Therapy for Lung Cancer First in Human Study Results presented at AABIP Read more »
First-in-Human Data to Be Presented at AABIP 2026 Prothea Technologies™ is pleased to announce that Dr Adam Marshall, Consultant Physician in Respiratory Medicine at the Royal Infirmary of Edinburgh, UK and Principal Investigator of the Precision Lung clinical […] Read more »
Research Partner Publishes Landmark Study Findings reinforce the potential of fluorescence lifetime imaging (FLIM) – the scientific foundation of Prothea’s molecular imaging technology. The Prothea Technologies team congratulates Professor Ahsan Akram, Dr Qiang Wang, Dr […] Read more »
First Patient Recruited in Precision Lung Clinical Study Prothea Technologies is pleased to announce the enrolment of the first patient in the Precision Lung clinical study (ISRCTN15093468). The study is co-sponsored by ACCORD, the joint research office between the […] Read more »
Prothea Technologies at AABIP 2025 Prothea Technologies, the private medical technology company with a vision to offer lung cancer biopsy and treatment in a single hospital visit, is pleased to announce that its technology will feature […] Read more »
Prothea Technologies at ECBIP 2025 Prothea Technologies, the private medical technology company with a vision to offer lung cancer biopsy and treatment in a single hospital visit, is pleased to announce that its technology will […] Read more »
Prothea Technologies Launches with €12M Series A to Innovate Lung Cancer Diagnosis and Treatment. Prothea Technologies launched with €12M Series A to address two main challenges in the management of lung cancer: inaccurate biopsies and limited interventional treatment options for small lesions. Round co-led […] Read more »